GSK_ Annual_Report_2021-22

81 of patients during the most difficult pandemic phases. This award is also a testament of the matured risk culture and management practices, with focus on delivering against our three culture pillars. Some material issues identified are as follows – ESG dimension Material issues Impact Management approach Business Ethics Prevention of bribery & corruption High The company is exposed to regulation around the prevention of bribery and corruption, including extra-territorial laws. Failure to comply could have significant financial and reputational consequences. We have stringent anti bribery and corruption (‘ABAC’) policies, governance, and compliance monitoring mechanisms in place to mitigate the risks. Data protection and cyber security High The company has access to employees’ data and administrative data from partners. We have a global data protection and cyber security policy. Breaches and threats are continuously monitored at the global level. Human Resources Occupational health & safety High Providing a safe and healthy workplace environment for our workers is critical to the success of our operations. Our focus is to create a workplace free of injuries, fatalities, and illness (both chronic and acute, and physical and mental health) by leveraging technology and through trainings, appropriate personal protective equipment, incident tracking and reporting. Training & development Very High Your company is focused on creating an enabling environment for our employees through carefully curated learning and development modules. We believe that this is critical to ensure retention of our skilled workforce and to consistently provide them with growth opportunities which improve their employability. Exposure to physical climate change risks High For our manufacturing operations, we have internal targets to reduce carbon emissions from our Nashik plant in order to mitigate our impact on climate change. Supply Chain Supply Chain Management High Our supplier and distribution network are widespread and inherently exposed to risks from disruption. We undertake detailed assessments of our suppliers and third-party contract manufacturers at the time of onboarding and periodically. These assessments cover a multitude of ESG topics like labour rights, fair wages, ABAC, and regulatory compliances. Social outcomes Product Quality and Patient Safety Very High We understand that we have a responsibility to provide our consumers with manufactured products that positively impact health outcomes for the society. Our Quality and Pharmacovigilance teams proactively tracks regulatory and non-regulatory complaints and grievances and works towards redressing them in an effective manner. Access and affordability Very High We are committed to ensure access and affordability of our pharmaceutical products within India by periodically assessing our product portfolio to make it more diversified. With the revised National List of Essential Medicines (NLEM) expected to be released by the government, we are engaging in various stakeholder discussions on the same. Other factors that could impact your company include government policies and evolving market landscape (e.g., channel disruption and digitization) Section B: Management and Process Disclosures The section aimed at helping businesses demonstrate the structures, policies and processes put in place towards adopting the NGRBC Principles and Core Elements. Disclosure Questions P1 P2 P3 P4 P5 P6 P7 P8 P9 Ethics and transparency Product responsibility Human resources Responsiveness to stakeholders Human rights Protect & restore environment Public policy advocacy Inclusive growth Customer engagement Policy and management processes 1. a. Whether your entity’s policy/ policies cover each principle and its core elements of the NGRBCs. (Yes/No) Y Y Y Y Y Y Y Y Y b. Has the policy been approved by the Board? (Yes/No) Y Y NA Y NA Y Y Y Y